Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.71 |
| ▸ | BCL2 | P10415 | 15/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409440 | 1.00 | BCL2L1 (0.71) | BCL2L1BCL2BAD | |
| SCHEMBL22409471 | 0.93 | BCL2L1 (0.73) | BCL2L1BCL2BAD | |
| SCHEMBL22409470 | 0.93 | BCL2L1 (0.73) | BCL2L1BCL2BAD | |
| SCHEMBL22409479 | 0.91 | BCL2L1 (0.71) | BCL2L1BCL2BAD | |
| SCHEMBL22409476 | 0.91 | BCL2L1 (0.71) | BCL2L1BCL2BAD | |
| SCHEMBL22409457 | 0.91 | BCL2L1 (0.72) | BCL2L1BCL2 | |
| SCHEMBL22409458 | 0.91 | BCL2L1 (0.72) | BCL2L1BCL2 | |
| SCHEMBL19145119 | 0.86 | BCL2L1 (0.84) | BCL2L1BCL2BAD | |
| SCHEMBL22409414 | 0.86 | BCL2L1 (0.78) | BCL2L1BCL2 | |
| SCHEMBL22409411 | 0.86 | BCL2L1 (0.78) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | BCL2L1 3463/4885BCL2 3060/4885BAD 3436/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | BCL2L1 3463/4885BCL2 3060/4885BAD 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.